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a b s t r a c t
3-Nitro-1H-1,2,4-triazole-based acetamides bearing a biphenyl- or a phenoxyphenyl moiety have shown
remarkable antichagasic activity both in vitro and in an acute murine model, as well as substantial in vitro
antileishmanial activity but lacked activity against human African trypanosomiasis. We have shown now
that by inserting a methylene group in the linkage to obtain the corresponding propanamides, both
antichagasic and in particular anti-human African trypanosomiasis potency was increased. Therefore,
IC50 values at low nM concentrations against both T. cruzi and T. b. rhodesiense, along with huge selec-
tivity indices were obtained. Although several propanamides were active against Leishmania donovani,
they were slightly less potent than their corresponding acetamides. There was a good correlation be-
tween lipophilicity (clogP value) and trypanocidal activity, for all new compounds. Type I nitroreductase,
an enzyme absent from the human host, played a role in the activation of the new compounds, which
may function as prodrugs. Antichagasic activity in vivo was also demonstrated with representative
propanamides.
© 2016 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
American trypanosomiasis (Chagas disease), human African
trypanosomiasis (HAT disease or sleeping sickness) and Leisma-
niasis are parasitic infections. They are considered neglected trop-
ical diseases (NTD) because they constitute a major health problem
in particularly poor countries around the world [1]. HAT disease
(caused by Trypanosoma brucei rhodesiense and T. b. gambiense) is
endemic throughout sub-Saharan Africa while Chagas disease
(caused by T. cruzi) affects populations in South and Central
America. In contrast, leishmaniasis (caused by Leishmania species)
is prevalent in many sub-tropical and tropical regions of the world,
recently expanding in non-tropical regions as HIV/AIDS co-
infection [2]. These insect transmitted diseases affect more than
20million people and are responsible for more than 110,000 deaths
per year [3]. HAT disease ranks high on the list of NTD because it is
fatal if untreated and the treatment options are limited. The inci-
dence of T. cruzi infection has signiﬁcantly declined recently, due to
implementation of vector control initiatives, however, the number
of cases in non-endemic sites (United States, Australia, Europe and
Japan) is rising, primarily due to human and vector migration and
contaminated blood transfusions [4e6].
The treatment of neglected diseases is based on drugs with
serious limitations. Thus, nifurtimox (Nfx) and benznidazole (Bnz),
the two currently used medications for Chagas disease (Fig. 1) are
associated with limited efﬁcacy, severe toxicity and long treatment
requirements [7,8]. Similarly, drugs used to treat HAT and
Abbreviations: NTD, Neglected tropical diseases; T. brucei, Trypanosoma brucei;
HAT, human African trypanosomiasis; T. cruzi, Trypanosoma cruzi; Bnz, benznida-
zole (N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide); Nfx, nifurtimox (4-(5-
nitrofurfurylindenamino)-3-methylthio-morpholine-1,1-dioxide); NTR, type I
nitroreductase; TcNTR, T. cruzi NTR; TbNTR, T. brucei NTR; CYP51, sterol 14a-
demethylase enzyme; TcCYP51, T. cruzi CYP51; IC50, concentration for 50% growth
inhibition; SI, selectivity index; SAR, structure-activity relationships; TDR, Tropical
Diseases Research (http://www.who.int/tdr/en/).
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leishmaniasis are highly toxic (e.g. melarsoprol, antimonials), or
require i.v. administration (e.g. melarsoprol, suramin, DFMO, anti-
monials) resulting in severe side effects, or are of high cost (e.g.
DFMO, liposomal amphotericin B, miltefosine and paromomycin)
[9e11]. Therefore, new effective, safe and affordable drugs are ur-
gently needed for the treatment of these neglected diseases.
We have demonstrated that various chemical classes of 3-nitro-
1H-1,2,4-triazole-based compounds, including aliphatic/aromatic
amines, amides, sulfonamides, carbinols, piperazines and piper-
azides (some of them shown in Fig. 1) exhibit excellent antichagasic
activity both in vitro and in vivo, with several analogs also showing
appreciable anti-T. b. rhodesiense activity in vitro. [12e18] Futher-
more, 3-nitrotriazole-based compounds are signiﬁcantly more
potent and less toxic than their 2-nitroimidazole-based counter-
parts [12e19]. Nfx, Bnz and other nitroheterocyclics work as pro-
drugs, needing enzymatic activation to exert their trypanocidal
activity [20e23]. We have previously shown that 3-nitrotriazole-
based compounds are excellent substrates of a type I nitroreductase
(NTR), an oxygen-insensitive nitroreductase present in the mito-
chondrion of trypanosomatids and absent from most other eu-
karyotes [20e23] and that part of the trypanocidal activity of these
compounds depends on the parasite's expression of type I NTR
[12,13,15e18,24].
Despite the failure of the antifungal drug posaconazole to treat
chronic Chagas disease in clinical trials [25], there is still a great
interest in developing more speciﬁc inhibitors of T. cruzi CYP51
(TcCYP51), the orthologous enzyme of the fungal sterol 14a-
demethylase enzyme (CYP51) [26e28]. Sterol 14a-demethylase is
crucial for the formation of viable membranes and the regulation of
metabolic processes such as cell growth and division, not only in
fungi but also in trypanosomatids [29e32]. Since the triazole ring
plays a signiﬁcant role in CYP51 inhibition [31], we have previously
evaluated 3-nitrotriazole-based amides with a linear, rigid core, as
well as 3-nitrotriazole-based carbinols (ﬂuconazole analogs) as
bifunctional agents; such compounds can act as substrates for type
I NTR in addition to being inhibitors of TcCYP51 [17]. These
bifunctional compounds demonstrated remarkable antichagasic
activity both in vitro and in an acute murine model [17]. A subclass
of such bifunctional antitrypanosomal agents was 3-nitrotriazole-
based aryloxyphenylacetamides, inwhich the 3-nitrotriazole ring is
separated from the amidic carbonyl by one methylene-group [24].
3-Nitrotriazole-based aryloxyphenylacetamides, besides being
very potent antichagasic agents in vitro and in vivo, demonstrated
also remarkable in vitro activity against L. donovani axenic amasti-
gotes, something that was not seen before with other 3-
nitrotriazole-based derivatives [24]. However, these acetamides
were only moderately active against T. b. rhodesiense, with poor
selectivity for this parasite, despite the fact that they were excellent
substrates of TbNTR [24].
Therefore, in the present work we tried to further optimize the
class of 3-nitrotriazole-based aryloxyphenylamides with the goal to
increase their anti-HAT activity. This was obtained via linkage
elongation between the nitrotriazole ring and the amidic carbonyl
by inserting one additional methylene group. Thus, novel 3-
nitrotriazole-based propanamides were synthesized and screened
for antitrypanosomal activity. The novel propanamides were then
compared side by side with the corresponding acetamides.
2. Results and discussion
2.1. Chemistry
The structure of the twelve novel compounds is shown in
Table 1, together with the structure of previously synthesized an-
alogs (in orange), for comparison purposes. The synthesis of the
new compounds in Table 1 is straightforward and based on well-
established chemistry, outlined in Scheme 1. Thus, acetamides 2,
3, 13 and 15 were obtained by nucleophilic substitution of the
appropriate chloroacetamide 1a-c with the potassium salt of 3-
nitro-1,2,4-triazole (and in the case of 3 the potassium salt of 2-
nitroimidazole) under reﬂuxing conditions. Similarly, prop-
anamides 6e12 and 14 were obtained by nucleophilic substitution
of the appropriate bromopropanamide 4a-h with the potassium
salt of 3-nitro-1,2,4-triazole under reﬂuxing conditions. During the
synthesis of bromopropanamides 4a-h, the acrylamides 5a-h were
also formed as b-elimination byproducts, which however were not
isolated due to a similar Rf value they share on TLC with bromo-
propanamides 4a-h. Fortunately, the acrylamides 5a-h not only did
not prevent the next step but in fact they furnished as starting
materials for the formation of the ﬁnal propanamides through
Michael addition. The ﬁnal compounds were obtained in 45e78%
yield.
Chloroacetamides 1a-c and bromopropanamides 4a-h were
prepared from appropriate, commercially available arylamines and
chloroacetyl chloride or 3-bromopropanoyl chloride, respectively,
in the presence of triethylamine, at room temperature.
2.2. Biological evaluation
2.2.1. Antiparasitic activity
Compounds in Table 1 were screened for anti-parasitic activity
against three trypanosomatids: T. cruzi, T. b. rhodesiense and
Leishmania donovani and compared with previously made analogs
shown in orange and designated with a. The concentration of
compound that inhibits parasite growth by 50% (IC50) was calcu-
lated from dose response curves for each parasite (Table 1). In
addition, compounds were tested for toxicity in L6 rat skeletal
myoblasts, the host cells for T. cruzi amastigotes, in order to
Fig. 1. The chemical structure of Bnz, Nfx and the general structure of representative classes of 3-nitrotriazole-based trypanocidal compounds (A: piperazides, B & C: amides, and D:
sulfonamides).
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Table 1
In vitro antiparasitic activity, host toxicity and physical properties of tested compounds.
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calculate a selectivity index for each parasite [SI¼ IC50L6/IC50parasite]
(Table 1). The TDR (Special Programme for Research and Training in
Tropical Diseases, World Health Organization) criteria were adop-
ted to interpret antiparasitic activity and selectivity [33].
According to the TDR criteria, all 3-nitrotriazole-based analogs
were selectively ‘active’ antichagasic agents (IC50 of <4.0 mM, SI of
50), whereas the 2-nitroimidazole-based analog 3 was ‘moder-
ately active’ against T. cruzi but with an unacceptable SI value (IC50
between 4.0 and 60 mM, SI < 50). The 3-nitrotriazole-based prop-
anamides (6e12) were similar to or more potent antichagasic
agents than the corresponding 3-nitrotriazole-based acetamides
(6a-11a and 13), most of the latter being previously evaluated
(highlighted in orange and designated with a).
All 3-nitrotriazole-based propanamides were ‘active’
(IC50 < 0.5 mM) (6e11) or ‘moderately active’ (IC50 between 0.5 and
6.0 mM) (12 and 14) anti-HAT agents that displayed acceptable
selectivity (SI of 100) towards T. b. rhodesiense (Table 1). Inter-
estingly, these compounds were up to 214-fold more potent against
this parasites than the corresponding acetamides (6a-11a, 13 and
15), with the latter structures being deemed ‘inactive’
(IC50 > 6.0 mM) or ‘moderately active’ at best. The increased anti-
HAT activity displayed by the propanamides relative to the acet-
amides was always accompanied with a favorable shift in selec-
tivity (Table 1).
The 3-nitrotriazole-based acetamide 2 was inactive against T. b.
rhodesiense, but still more potent than the corresponding 2-
nitroimidazole-based analog 3, whereas compound 2a of equal
molecular weight with 2 was 5.8-fold more potent against T. b.
rhodesiense than 2, suggesting the importance of the amidic proton.
Previously we have found that 3-nitrotriazole-based aryloxy-
phenylamides are selectively ‘active’ against L. donovani amasti-
gotes in vitro (IC50 < 1 mM, SI 20). Increasing the distance between
the nitrotriazole ring and the amidic carbonyl in compounds 6e11
and 14 sustained antileishmanial activity, although a shift to
‘moderate activity’ (IC50 between 1.0 and 6.0 mM) was observed for
propanamides 6e8 in comparison with their acetamide-analogs
6a-8a (Table 1).
2.2.2. SAR analysis of antichagasic activity
The 3-nitrotriazole-based acetamide 2, having an N-methyl
substituent, was synthesized to be compared with the previously
evaluated acetamide 2a, which is unsubstituted on the amidic ni-
trogen but of equal molecular weight with 2. This N-substitution in
2 resulted in a 1.6-fold decrease in antichagasic activity compared
to 2a, but also in a 2-fold decrease in toxicity against L6 cells,
despite the fact that 2 was slightly more lipophilic than 2a (clogP
1.99 vs 1.83). Thus, the SI of 2 was also slightly higher than that of
2a. However, both compounds were slightly more potent anti-
chagasic agents than Bnz (Table 1).
Acetamide 2was also compared as antichagasic agent with its 2-
nitroimidazole-based counterpart 3. In keeping with our previous
ﬁndings the former structure was shown to be 32-fold more potent
towards Trypanosoma cruzi amastigotes than the latter. In addition,
compound 3 was shown to display a higher degree of toxicity to-
wards L6 cells compared to 2, presumably due to its higher lip-
ophility (Table 1). Together these initial phenotypic screens
Scheme 1. Synthesis of compounds on Table 1.
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demonstrate that 3 had an unfavorable SI score (~4) relative to that
determined for 2 (~165) with these results suggesting once again
that 3-nitrotriazole-based compounds may be better antichagasic
agents than 2-nitroimidazole-based analogs, at least in vitro.
Evaluation of the antichagasic properties of the nitrotriazole-
based phenyloxyphenyl propanamides (6e8) with their acet-
amide counterparts (6a-8a) revealed that for each compound
pairing similar potencies towards the parasite were observed
(Table 1). However, due to their greater lipophilicity, propanamides
displayed an increased toxicity towards L6 cells. Despite this issue,
the nitrotriazole-based phenyloxyphenyl propanamides exhibited
very encouraging SI values for T. cruzi (398e3343). The
nitrotriazole-based p-chlorophenyloxyphenyl propanamide 6 was
an extremely potent antichagasic agentwith an IC50 of 5 nM against
T. cruzi amastigotes, slightlymore potent than the acetamide analog
6a (IC50 of 8 nM). This was not the case with the ﬂuorinated analogs
7 and 7a and the unsubstituted pairs 8 and 8a. Both acetamides 7a
and 8a appeared slightly better as antichagasic agents than their
propanamide-analogs 7 and 8 (Table 1). Antichagasic activity (as
well as toxicity in L6 cells) decreased from the chloro-to the ﬂuoro-,
to the non-substituted phenyloxyphenyl-propanamide or acet-
amide, presumably as a result of decreasing lipophilicity rather
than electronegativity of the substituent, since ﬂuorine is more
electronegative than chlorine (Table 1).
The growth inhibitory effect of nitrotriazole-based biphenyla-
mides (9, 9a, 10 and 10a) towards T. cruzi and L6 cells was also
assessed (Table 1). There was about 1.5-fold increase in potency of
p-cyanobiphenyl-propanamide 9 against T. cruzi parasites
compared to acetamide analog 9a. In addition, propanamide 9 was
less toxic to L6 cells compared to 9a, despite its slightly higher
lipophilicity. This reduced toxicity towards L6 cells coupled with
the increased potency towards T. cruzi parasites resulted in a better
SI of 9 compared to that of 9a (Table 1). A greater clogP value inm-
biphenyl-propanamide 10 resulted in a 2.2-fold better antichagasic
activity, with slightly increased toxicity to L6 cells compared to its
acetamide analog 10a,without, however, compromising selectivity.
A drastic reduction in mammalian cell toxicity was noted for the
two cyano-containing biphenylamides 9 and 9a, being >6- and
>3.5-fold less toxic towards L6 cells, respectively, relative to
unsubstituted compounds 10 and 10a. This reduction in mamma-
lian cell toxicity, which may be related to both the electron with-
drawing effect of the p-cyano group (inductive and resonance
effects) as well as the para-position of the biphenyls in compounds
9 and 9a, resulted in superior SI values compared to those obtained
for compounds 10 and 10a (Table 1).
Antichagasic activity and selectivity was improved also in them-
benzyloxyphenyl propanamide 11, compared to its acetamide
analog 11a. The slightly greater lipophilicity of 11 resulted in a
slightly increased toxicity towards L6 cells, without, however,
compromising selectivity towards the parasite.
Finally, four novel 3-nitrotriazole based phenylisoxazole-
acetamides/propanamides (12e15) were also evaluated for anti-
chagasic activity in vitro. The p-ﬂuorophenyl-isoxazole prop-
anamide 12, inwhich the p-ﬂuorophenyl group is attached in the 5-
position of the isoxazole ring was similarly active as an antichagasic
agent with the acetamide analog 13. Despite being more lipophilic
than 13, propanamide 12 was less toxic towards L6 cells, thus
yielding a greater SI compared to 13. In contrast, the p-chlor-
ophenylisoxazole-propanamide 14, in which the p-chlorophenyl
group is attached in the 3-position of the isoxazole ring, was 6-fold
more active as an antichagasic agent than its acetamide analog 15.
Moreover, propanamide 14 was about 10-fold more selective to-
wards this parasite than acetamide 15. The slightly greater clogP
value of 14 may have played a role in its increased antichagasic
activity but did not explain its decreased cytotoxicity towards L6
cells compared to 15.
Plotting logIC50 values against T. cruzi amastigotes versus clogP
values for all novel compounds in Table 1, we obtained a good
correlation between antichagasic activity and lipophilicity (Fig. 2).
Correlation between lipophilicity and cytotoxicity towards L6 cells
lead to an R2 of only 0.62, indicating that lipophilicity alone did not
account for toxicity.
The amidic pKa value does not seem to play a role in the anti-
chagasic activity of propanamides versus acetamides although
more acidic amides seem to be less potent antichagasic agents
(Table 1).
All novel compounds in Table 1 were 1.4- to 441-fold better
antichagasic agents than Bnz (Table 1).
2.2.3. SAR analysis of anti-HAT activity
Evaluation of the growth inhibitory effects of the 3-
nitrotriazole-based acetamides 2 & 2a and their 2-
nitroimidazole-based analog 3 against T. b. rhodesiense revealed
the following: ﬁrstly, all three were characterized ‘inactive’ anti-
HAT agents according to the TDA criteria. Secondly, N-methyl-
ation in 2 resulted in a decreased anti-HAT activity compared to 2a
of an equal molecular weight, demonstrating the importance of the
amidic hydrogen for trypanocidal activity. This decrease in the anti-
HAT activity of 2was even greater than the corresponding decrease
in its antichagasic activity compared to 2a. Finally, compound 3was
also signiﬁcantly less potent as anti-HAT agent compared to both 2
and 2a, showing yet again the inferior trypanocidal properties of 2-
nitroimidazole-based compounds relative to their 3-nitrotriazole-
based counterparts.
The phenotypic screens were then extended to evaluate the
susceptibility of T. b. rhodesiense to 3-nitrotriazole-based prop-
anamides (6e12, 14) relative to their acetamide-analogs (6a-11a,
13, 15). For each propanamide/acetamide pairing it was clear that
the former compounds were signiﬁcantly more potent towards this
parasite than the latter with the propanamide derivatives deemed
‘active’ (6e11) or ‘moderately active’ (12, 14) anti-HAT agents
relative to acetamides that were largely classed as ‘moderately
active’ (6a-8a,11a), or ‘inactive’ (10a,13,15). The increased potency
of the propanamides towards T. b. rhodesiense consistently trans-
lated to improved SI values.
Closer examination of the susceptibility data revealed that for
the phenoxyphenyl-containing structures the p-chloro-substituted
propanamide 6 was 32-fold more potent towards T. b. rhodesiense
than its acetamide analog 6a, the p-ﬂuoro-substituted prop-
anamide 7 was 12-fold more potent than 7a whereas the unsub-
stituted propanamide 8 was 17.4-fold more potent than 8a. A
smaller shift towards lower IC50 values against T. b. rhodesiensewas
observed in the pair 9 and 9a, since acetamide 9a was already an
y = -1.4114x + 3.0272
R² = 0.7813
-3.000
-2.500
-2.000
-1.500
-1.000
-0.500
0.000
0.500
1.000
1.500
2.000
0 1 2 3 4
T.
 c
ru
zi
 lo
gI
C 5
0
clogP
Fig. 2. Correlation between lipophilicity (clogP values) and activity against T. cruzi
(logIC50 values) of all novel compounds in Table 1.
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active anti-HATagent. Therefore the p-cyanobiphenyl propanamide
9 was only 3.7 fold more potent as an anti-HAT agent than the
corresponding acetamide 9a (Table 1).
An enormous shift to anti-HAT activity was observed in prop-
anamide 10 compared to acetamide 10a. Thus, m-biphenyl prop-
anamide 10 was 214-fold more potent against T. b. rhodesiense
compared to the corresponding acetamide 10a, which was inactive
against this parasite. This increase in the anti-HAT activity of 10
cannot be explained only by its greater lipophilicity compared to
10a, since a similar difference in lipophilicity in the pair 6 and 6a
did not have the same effect in anti-HAT activity.
A shift from ‘moderately active’ to ‘active’ anti-HAT agent
occurred in the case of the m-benzyloxyphenyl-based compounds
with the propanamide 11 being 22-fold more active against T. b.
rhodesiense than the corresponding acetamide 11a (Table 1). A
similar shift in anti-HAT activity was noted for the phenylisoxazole
pairs 12 & 13 and 14 & 15. Therefore, from the inactive p-ﬂuo-
rophenylisoxazole acetamide 13 and p-chlorophenylisoxazole
acetamide 15we obtained the ‘moderately active’ propanamides 12
and 14, respectively. Propanamide 12was 5.6-fold more active than
acetamide 13 and propanamide 14 was 23-fold more active than
acetamide 15 (Table 1).
As in the case of antichagasic activity, there was an even better
correlation between lipophilicity (clogP values) and anti-HAT ac-
tivity (logIC50 values against T. b. rhodesiense), with an R2 of 0.85
(Fig. 3). However, lipophilicity alone cannot explain the huge in-
crease observed in the anti-HAT activity of propanamides vs acet-
amides. Interestingly, all propanamides demonstrated a larger pKa
value than acetamides for the amidic ionization, which means that
more acidic amides are less potent anti-HAT agents (Table 1).
However, it is not clear if these in vitro active propanamides will
exert anti-HAT activity in vivo, because they demonstrate relatively
high PSA values (115e132), which may not permit penetration of
the blood-brain barrier and thus targeting of infected tissue in the
central nervous system.
2.2.4. SAR analysis of antileishmanial activity
Linkage elongation between the nitrotriazole ring and the
amidic carbonyl by one methylene group resulted in an ~6- to 34-
fold decreased antileishmanial activity in propanamides 6e8
compared to acetamides 6a-8a, designating propanamides 6e8
‘moderately active’ against this parasite. In addition, this shift to
larger IC50 values resulted in unacceptable SI values (<20) for
compounds 6 and 8. (Table 1). A shift to decreased antileishmanial
activity and an unacceptable SI value was also observed in
propanamide 10 compared to acetamide-analog 10a. Propanamide
9 was moderately active against L. donovani and with a good
selectivity but it could not be compared to acetamide 9a because
the antileishmanial activity of the latter was not determined. In
contrast, an increase in antileishmanial activity and selectivity was
observed in propanamides 11, 12 and 14 compared to acetamide
analogs 11a, 13 and 15. Although the benzyloxyphenyl-
propanamide 11 demonstrated moderate activity against
L. donovani according to the criteria set, it was ca. 3-fold more
potent than the acetamide analog 11a, with both exhibiting
acceptable SI values (Table 1).
In the case of the p-ﬂuorophenylisoxazoles 12 and 13, we can
observe that the IC50 value of propanamide 12 was slightly lower
than that of acetamide 13, although both were deemed ‘inactive’
against L. donovani. In contrast, the p-chlorophenylisoxazole-
propanamide 14 was ‘moderately active’ against L. donovani and
with an acceptable selectivity, whereas the corresponding acet-
amide 15 was ‘inactive’ against this parasite (Table 1).
Once again, there was a good correlation between lipophilicity
and antileishmanial activity (R2 ¼ 0.78) for the novel compounds
(data not shown) but in this case increased antileishmanial activity
was associated with increased amidic acidity in pairs 6-6a, 7-7a, 8-
8a, and 10e10a while decreased antileishmanial activity was
associated with increased acidity in pairs 11e11a, 12e13 and 14e15
(Table 1).
2.2.5. Involvement of type I nitroreductase
To elucidate themechanism of action of the novel compounds in
Table 1, representative 3-nitrotriazole-based propanamides (6e8,
10, 11, 14) and acetamides (13, 15) were evaluated as substrates of
puriﬁed, recombinant TbNTR and compared to benznidazole
(Fig. 4). Enzyme speciﬁc activity was measured as oxidized NADH
(nmol) per min per mg of protein. Compounds 9 and 12 were also
analyzed but these precipitated in the assay buffer and no activity
could be determined. All remaining compounds were shown to be
substrates of TbNTR, with compounds 6, 11 and 13 yielding speciﬁc
enzyme activity values up to ~4-fold greater than benznidazole. In
the only propanamide/acetamide pairing tested (14, 15), TbNTR
metabolized both compounds at equivalent rates despite the
former exhibiting greater anti-HAT activity [24]. As we have re-
ported before with other classes of 3-nitrotriazole-based anti-
trypanosomal compounds, no correlation between anti-HAT
activity and TbNTR speciﬁc activity was observed [12,13,15e18].
When the above biochemical tests were extended to phenotypic
screens, BSF T. b. brucei parasites engineered to express elevated
levels of TbNTR were shown to be more susceptible to the
y = -1.6303x + 4.2739
R² = 0.8506
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compounds under study than controls, thus indicating that within
the parasite the nitrotriazoles are functioning as TbNTR activated
prodrugs (Table 2). Intriguingly, the ratio of the IC50 values between
the recombinant line and wild type did vary from agent to agent.
For some compounds (e.g. 6 and 7) the fold difference between the
two lines was low (~2-fold) with these structures generally
exhibiting a moderate anti-T. b. brucei activity against wild type
parasites (IC50 values of ~0.65 mM). In contrast, the TbNTR over-
expressing line was shown to be 10- to 25-fold more susceptible to
other agents (e.g.10,11, and 15) that exhibit a lower potency against
control lines to start with (IC50 values of 4e8 mM). Together this
indicates that for compounds which are less effective against wild
type T. b. brucei it is the activation step that appears to limit their
trypanocidal potential. When the rate limiting reaction is allevi-
ated, in this case through the over expression of the trypanosomal
type I NTR activity, then most of the nitrotriazoles tested exhibit
equivalent potencies towards the parasite at which point other
downstream factors may now be affecting the anti-T. b. brucei
activity.
2.2.6. In vivo evaluation
Compounds 6, 7 and 9were chosen for in vivo evaluation, based
on their high in vitro potency and selectivity against Trypanosoma
cruzi amastigotes (Table 1). A fast luminescence assay was used in
an acute infected murine model, in which transgenic T. cruzi par-
asites expressing ﬁreﬂy luciferase were injected in 5 week-old Balb/
c mice. Mice were injected with D-luciferin before imaging. Groups
of 5 mice/group were treated i.p. for 10 consecutive days with each
compound, at 13 or 15 mg/kg/day. In our previous work with 3-
nitrotriazole-based rigid amides we have seen very good in vivo
antichagasic activity at daily doses of 15 mg/kg [17], therefore we
decided to use a slightly lower dose for compounds 6 and 7 which
demonstrated IC50 values against T. cruzi amastigotes at low nM
concentrations (Table 1). Bnz was used in parallel as a positive
control at 15 mg/kg/day (i.p.). The mean ratio of parasite levels was
calculated after 5 and 10 days of treatment. The data are summa-
rized in Fig. 5. All tested compounds, including Bnz, reduced the
parasite load to undetectable levels after 10 days of treatment with
statistical signiﬁcance (p < 0.0001). Statistically signiﬁcant reduc-
tion in parasitic level (compared to untreated control) was also
observed after 5-day treatment with each compound. However,
mice in the group treated with compound 6 did not look very
healthy, although no deaths occurred. Compound 6 demonstrates
the lowest IC50 value in L6 cells among all analogs tested (Table 1),
and perhaps a smaller dose should have been used in mice. No
toxicity symptoms were observed with compounds 7 and 9.
3. Conclusions
3-Nitrotriazole-based propanamides with a broad spectrum of
antitrypanosomalactivitywere synthesized. The invitroantichagasic
activity of propanamideswas excellent and comparable to that of the
corresponding acetamides. However, their in vitro anti-HAT activity
was 4- to 214-fold greater than that of the corresponding acetamide
analogs. With regard to the antileishmanial activity, a decrease was
observed for some propanamides whereas a comparable or greater
activitywas observed forothers in comparisonwith their acetamide-
analogs. Antitrypanosomal activity was in good correlation with
lipophilicity. Decreased amidic acidity tended to favor anti-HAT ac-
tivity whereas increased amidic acidity tended to favor anti-
leishmanial activity inmostof thecompounds. 3-Nitrotriazole-based
propanamides are good substrates for type I NTR, but no better than
the corresponding acetamides. There was no correlation between
enzymatic speciﬁc activityandtrypanocidal activity, presumablydue
to the existence of additional targets in the trypanosome, perme-
ability issues with regard tomitochondrion, compound stability and
pharmacokinetic factors in general. Such lack of correlation was
observed and discussed before with other classes of 3-nitrotriazole-
based antitrypanosomal agents [12,13,15e18]. With regard to po-
tential additional targets, it was demonstrated that in addition to
type I NTR activation, Bnz toxicity against Trypanosoma cruzi is
mediated by various othermechanisms including thiol depletion (by
Bnz reductionproducts) [34], interferon-gmediated activationof the
immune system [35], andNADH-fumarate inhibition [36]. Therefore,
further investigation is needed to elucidate if additional enzymes are
involved in the mechanism of action of 3-nitrotriazole-based prop-
anamides as well as the role of CYP51.
Representative 3-nitrotriazole-based propanamides demon-
strated very good antichagasic activity in an acute T. cruzi murine
model, but further investigation is required to see if such com-
pounds can provide cures in the chronic model, taking into account
also toxicity issues.
4. Experimental
4.1. Chemistry
4.1.1. General
All starting materials and solvents were purchased from Sigma-
Table 2
Susceptibility of bloodstream form T.b. brucei with altered levels of NTR towards
selected nitrotriazoles.
Compound IC50 value (mM) T.b. brucei Ratio etet/þtet
Wild type TbNTR (-tet) TbNTR (þtet)
nfx 3.98 ± 0.15 6.359 ± 0.119 0.869 ± 0.046 7.3
6 0.64 ± 0.02 0.62 ± 0.03 0.34 ± 0.00 1.8
7 0.57 ± 0.05 0.68 ± 0.07 0.33 ± 0.03 2.1
8 0.14 ± 0.01 1.47 ± 0.03 0.41 ± 0.01 3.6
9 0.12 ± 0.01 0.55 ± 0.04 0.12 ± 0.01 4.7
10 6.66 ± 0.92 5.58 ± 0.62 0.23 ± 0.02 24.6
11 4.25 ± 0.16 3.70 ± 0.58 0.36 ± 0.02 10.4
12 0.76 ± 0.10 1.61 ± 0.10 0.40 ± 0.00 4.1
13 26.61 ± 6.02 e e
14 0.27 ± 0.05 0.91 ± 0.03 0.29 ± 0.02 4.2
15 8.65 ± 0.49 13.27 ± 1.40 1.23 ± 0.06 10.8
Growth-inhibitory effect as judged by IC50 values (in mM) of selected 3-nitroriazoles
on T.b. brucei wild type and recombinant parasites expressing wild type [TbNTR
(-tet)] or elevated [TbNTR (þtet)] levels of TbNTR. Data are means from 4
experiments ± standard deviation. Nifurtimox (nfx) was used as control. Only
compounds exhibiting an IC50 < 10 mM in wild type parasites were screened against
the recombinant line.
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Fig. 5. In vivo evaluation of the antichagasic efﬁcacy of compounds 6, 7, 9 and Bnz in
the acute murine model. Compounds 6 and 7 were administered (i.p.) at 13 mg/kg/day
while compound 9 and Bnz were administered at 15 mg/kg/day (i.p.) up to 10
consecutive days. Parasite ratios were calculated on day 5 and 10. The P values be-
tween each treated group and control group for 5-day treatment are shown on the
graph. The P value was 0.0001 between each treated group and control group for 10-
day treatment. Groups of 5 mice/group were used.
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Aldrich (Milwaukee, WI), were of research-grade quality and used
without further puriﬁcation. Solvents usedwere anhydrous and the
reactions were carried out under a nitrogen atmosphere and
exclusion of moisture. Melting points were determined by using a
Mel-Temp II Laboratory Devices apparatus (Holliston, MA) and are
uncorrected. Proton NMR spectra were obtained on a Varian Inova-
500 or an Agilent Hg-400 spectrometer at 500 or 400 MHz,
respectively, and are referenced to Me4Si or to the corresponding
solvent, if the solvent was not CDCl3. High-resolution electrospray
ionization (HRESIMS) mass spectra were obtained on an Agilent
6210 LC-TOF mass spectrometer at 11,000 resolution. Thin-layer
chromatography was carried out on aluminum oxide N/UV254 or
polygram silica gel G/UV254 coated plates (0.2 mm, Analtech,
Newark, DE). Chromatography was carried out on preparative TLC
alumina GF (1000 mm) or silica gel GF (1500 mm) plates (Analtech).
All ﬁnal compounds were puriﬁed by preparative TLC chromatog-
raphy on silica gel plates and also checked by HPLC (Agilent 1100)
coupled to mass spectrometry (MS) and ultraviolet (UV) absor-
bance detectors. Purity was determined by comparing the area
under the curve of the test compound peak to the combined areas
of all peaks in the chromatogram, excluding DMSO and any peaks
appearing in blank runs. Priority reporting was given to the UV
traces (since mass spectrometer response can vary widely
depending on a given compound's ease of ionization). Purity of
compounds lacking UV activity was reported using mass spec-
trometry detection. All ﬁnal compounds were 100% pure, according
to HPLC-UV analysis.
4.1.2. Synthesis of precursors 1a-c and (4 þ 5)a-h
Compounds 1a-c and (4þ 5)a-hwere synthesized as follows: In
a dichloromethane solution (3 mL) of chloroacetylchloride (1.1 eq)
or 3-bromopropanoyl chloride (1.1 eq), a dichloromethane solution
(8e10 mL) of the appropriate amine (1 eq, usually 200e300 mg)
and triethylamine (1.1 eq) was added dropwise and the reaction
mixture was stirred overnight at room temperature under a ni-
trogen atmosphere. The reaction mixture was evaporated and
redissolved in ethyl acetate. The inorganic salts were ﬁltered away
and the ﬁltrate was evaporated to give the desire product in
80e85% yield, which however, in most cases contained the corre-
sponding acrylamide (5a-h) as a b-elimination byproduct. In
certain cases, chromatography was applied to separate the bro-
mides from the acrylamides for identiﬁcation purposes, however in
most cases the unpuriﬁed mixture was used for the next step, since
both precursors lead to the desired ﬁnal product. The spectroscopic
data of compounds 1a-c and 4a-h (as well as of some acrylamide
byproducts) are provided in the Supplementary Material.
4.1.3. General synthesis of nitro(triazolyl/imidazolyl)acetamides
and propanamides 2, 3, 6e15
The potassium salt of 3-nitro-1,2,4-triazole or 2-nitroimidazole
(1 eq, usually 100 mg) was formed in CH3CN (6e10 mL), by
reﬂuxing with KOH (1.2 eq) for 30 min. To this suspension 1a-c or
(4 þ 5)a-h (1.1 eq) was added and the reaction mixture was
reﬂuxed under a nitrogen atmosphere for 10 h. The reaction
mixture was checked by TLC for completion of the reaction and the
solvent was evaporated. The residue was dissolved in ethyl acetate
and the inorganic salts were ﬁltered away. Upon preparative TLC
(silica gel; ethyl acetate-petroleum ether), the desired product was
obtained usually as a powder. Purity was checked also by HPLC and
it was 100%.
4.1.3.1. N-methyl-2-(3-nitro-1H-1,2,4-triazol-1-yl)-N-(4-(tri-
ﬂuoromethyl)phenyl)acetamide (2). White microcrystals (216 mg,
64%): mp 133e134 C; 1H NMR (400 MHz, CDCl3) d: 8.35 (s, 1H,
triazolic), 7.82 (d, J ¼ 8.0 Hz, 2H, phenylic), 7.47 (d, J ¼ 8.4 Hz, 2H,
phenylic), 4.83 (s, 2H, COCH2-), 3.37 (s, 3H, CH3). HRESIMS calcd for
C12H11F3N5O3 and C12H10F3N5NaO3 m/z [MþH]þ and [MþNa]þ
330.0809 and 352.0628, found 330.0806 and 352.0619.
4.1.3.2. N-methyl-2-(2-nitro-1H-imidazol-1-yl)-N-(4-(tri-
ﬂuoromethyl)phenyl)acetamide (3). Thick oil that solidiﬁed to
yellowish crystals (180 mg, 62%): mp 45e47 C; 1H NMR (400 MHz,
CDCl3) d: 7.82 (d, J ¼ 8.0 Hz, 2H, phenylic), 7.55 (d, J ¼ 8.4 Hz, 2H,
phenylic), 7.18 (s, 1H, imidazolic), 7.02 (s, 1H, imidazolic), 4.86 (s,
2H, COCH2-), 3.36 (s, 3H, CH3). HRESIMS calcd for C13H12F3N4O3 and
C13H11F3N4NaO3m/z [MþH]þ and [MþNa]þ 329.0856 and 351.0675,
found 329.0849 and 351.0669.
4.1.3.3. N-(4-(4-chlorophenoxy)phenyl)-3-(3-nitro-1H-1,2,4-triazol-
1-yl)propanamide (6). Off white powder (126 mg, 48%): mp
138e140 C; 1H NMR (400 MHz, CD3COCD3) d: 9.37 (br s, 1H,
amidic), 8.66 (s, 1H, triazolic), 7.64 (d, J ¼ 9.2 Hz, 2H, phenylic), 7.37
(d, J ¼ 9.2 Hz, 2H, phenylic), 6.98 (dd, J ¼ 9.2, 6.4 Hz, 4H, phenylic),
4.74 (t, J ¼ 6.4 Hz, 2H, COCH2CH2-), 3.13 (t, J ¼ 6.4 Hz, 2H,
COCH2CH2-). HRESIMS calcd for C17H15ClN5O4 and C17H14ClN5NaO4
m/z [MþH]þ and [MþNa]þ 388.0807, 390.0784 and 410.0627,
412.0604, found 388.0806, 390.0786 and 410.0628, 412.0605.
4.1.3.4. N-(4-(4-ﬂuorophenoxy)phenyl)-3-(3-nitro-1H-1,2,4-triazol-
1-yl)propanamide (7). Off white microcrystals (174 mg, 58%): mp
124e125 C; 1H NMR (400 MHz, CD3COCD3) d: 9.34 (br s, 1H,
amidic), 8.66 (s, 1H, triazolic), 7.61 (d, J ¼ 9.2 Hz, 2H, phenylic), 7.13
(t, J ¼ 9.2 Hz, 2H, phenylic), 7.024e6.99 (m, 2H, phenylic), 6.94 (d,
J ¼ 9.2 Hz, 2H, phenylic), 4.74 (t, J ¼ 6.4 Hz, 2H, COCH2CH2-), 3.12 (t,
J ¼ 6.4 Hz, 2H, COCH2CH2-). HRESIMS calcd for C17H15FN5O4 and
C17H14FN5NaO4 m/z [MþH]þ and [MþNa]þ 372.1103 and 394.0922,
found 372.1104 and 394.0924.
4.1.3.5. 3-(3-Nitro-1H-1,2,4-triazol-1-yl)-N-(4-phenoxyphenyl)prop-
anamide (8). Light yellow microcrystals (172 mg, 57%): mp
108e110 C; 1H NMR (400 MHz, CD3COCD3) d: 9.35 (br s, 1H,
amidic), 8.66 (s, 1H, triazolic), 7.62 (d, J ¼ 8.8 Hz, 2H, phenolic), 7.35
(dt, J ¼ 7.6, 1.2 Hz, 2H, phenolic), 7.09 (t, J ¼ 7.6 Hz, 1H, phenolic),
6.96 (dd, J ¼ 9.6, 2.0 Hz, 4H, phenolic), 4.74 (t, J ¼ 6.4 Hz, 2H,
COCH2CH2-), 3.13 (t, J ¼ 6.4 Hz, 2H, COCH2CH2-). HRESIMS calcd for
C17H16N5O4 and C17H15N5NaO4 m/z [MþH]þ and [MþNa]þ 354.1197
and 376.1016, found 354.120 and 376.1018.
4.1.3.6. N-(40-cyano-[1,10-biphenyl]-4-yl)-3-(3-nitro-1H-1,2,4-
triazol-1-yl)propanamide (9). Off white microcrystals (120 mg,
48%): mp 200e204 C (dec.); 1H NMR (400MHz, CD3COCD3) d: 9.50
(br s, 1H, amidic), 8.69 (s, 1H, triazolic), 7.87e7.69 (m, 8H, phenylic),
4.76 (t, J ¼ 6.4 Hz, 2H, COCH2CH2-), 3.18 (t, J ¼ 6.4 Hz, 2H,
COCH2CH2-). HRESIMS calcd for C18H15N6O3 and C18H14N6NaO3 m/z
[MþH]þ and [MþNa]þ 363.120 and 385.102, found 363.1205 and
385.1017.
4.1.3.7. N-([1,10-biphenyl]-3-yl)-3-(3-nitro-1H-1,2,4-triazol-1-yl)
propanamide (10). White powder (121 mg, 65%): mp 174e176 C;
1H NMR (400 MHz, CD3COCD3) d: 9.42 (br s, 1H, amidic, 8.68 (s, 1H,
triazolic), 7.96 (d, J ¼ 2.0 Hz, 1H, phenylic), 7.62e7.34 (m, 8H,
phenylic), 4.76 (t, J ¼ 6.4 Hz, 2H, COCH2CH2-), 3.17 (t, J ¼ 6.4 Hz, 2H,
COCH2CH2-). HRESIMS calcd for C17H16N5O3 and C17H15N5NaO3 m/z
[MþH]þ and [MþNa]þ 338.1248 and 360.1067, found 338.1251 and
360.1071.
4.1.3.8. N-(3-(benzyloxy)phenyl)-3-(3-nitro-1H-1,2,4-triazol-1-yl)
propanamide (11). White microcrystals (81 mg, 45%): mp
119e120 C; 1H NMR (400 MHz, CD3COCD3) d: 9.30 (br s, 1H,
amidic), 8.66 (s, 1H, triazolic), 7.48e7.33 (m, 6H, phenylic), 7.19 (t,
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J ¼ 8.4 Hz, 1H, phenylic), 7.09 (d, J ¼ 8.8 Hz, 1H, phenylic), 6.72 (dd,
J¼ 8.0,1.6 Hz,1H, phenylic), 5.08 (s, 2H, benzylic), 4.73 (t, J¼ 6.8 Hz,
2H, COCH2CH2-), 3.12 (t, J¼ 6.4 Hz, 2H, COCH2CH2-). HRESIMS calcd
for C18H18N5O4 and C18H17N5NaO4 m/z [MþH]þ and [MþNa]þ
368.1353 and 390.1173, found 368.1356 and 390.1178.
4.1.3.9. N-(5-(4-ﬂuorophenyl)isoxazol-3-yl)-3-(3-nitro-1H-1,2,4-
triazol-1-yl)propanamide (12). White powder (197 mg, 75%): mp
215 C (dec); 1H NMR (400 MHz, CD3COCD3) d: 10.23 (br s, 1H,
amidic), 8.69 (s, 1H, triazolic), 7.95 (dd, J¼ 9.2, 5.6 Hz, 2H, phenylic),
7.32 (t, J ¼ 9.2 Hz, 2H, phenylic), 7.27 (s, 1H, isoxazolic), 4.79 (t,
J ¼ 6.4 Hz, 2H, COCH2CH2-), 3.29 (t, J ¼ 6.4 Hz, 2H, COCH2CH2-).
HRESIMS calcd for C14H12FN6O4 and C14H11FN6NaO4 m/z [MþH]þ
and [MþNa]þ 347.0899 and 369.0718 found 347.0906 and
369.0724.
4.1.3.10. N-(5-(4-ﬂuorophenyl)isoxazol-3-yl)-2-(3-nitro-1H-1,2,4-
triazol-1-yl)acetamide (13). White powder (120 mg, 46%):
mp > 220 C; 1H NMR (400 MHz, CD3COCD3) d: 10.67 (br s, 1H,
amidic), 8.78 (s, 1H, triazolic), 7.97 (dd, J¼ 9.2, 5.6 Hz, 2H, phenylic),
7.33 (t, J ¼ 8.8 Hz, 2H, phenylic), 7.28 (s, 1H, isoxazolic), 5.59 (s, 2H,
COCH2-). HRESIMS calcd for C13H10FN6O4 and C13H9FN6NaO4 m/z
[MþH]þ and [MþNa]þ 333.0742 and 355.0562, found 333.0743 and
355.0564.
4.1.3.11. N-(3-(4-chlorophenyl)isoxazol-5-yl)-3-(3-nitro-1H-1,2,4-
triazol-1-yl)propanamide (14). Off white microcrystals (220 mg,
78%): mp 207e209 C; 1H NMR (400MHz, CD3COCD3) d: 10.85 (br s,
1H, amidic), 8.69 (s, 1H, triazolic), 7.90 (d, J ¼ 8.4 Hz, 2H, phenylic),
7.54 (d, J ¼ 8.4 Hz, 2H, phenylic), 6.72 (s, 1H, isoxazolic), 4.81 (t,
J ¼ 6.4 Hz, 2H, COCH2CH2-), 3.32 (t, J ¼ 6.4 Hz, 2H, COCH2CH2-).
HRESIMS calcd for C14H12ClN6O4 and C14H11ClN6NaO4 m/z [MþH]þ
and [MþNa]þ 363.0603, 365.0579 and 385.0423, 387.0398 found
363.0606, 365.0581 and 385.0422, 387.0392.
4.1.3.12. N-(3-(4-chlorophenyl)isoxazol-5-yl)-2-(3-nitro-1H-1,2,4-
triazol-1-yl)acetamide (15). Pinkish powder (130 mg, 71%): mp
215e217 C; 1H NMR (400 MHz, CD3COCD3) d: 11.26 (br s, 0.5H,
amidic), 8.78 (s, 1H, triazolic), 7.91 (d, J ¼ 8.8 Hz, 2H, phenylic), 7.54
(d, J ¼ 8.8 Hz, 2H, phenylic), 6.78 (s, 1H, isoxazolic), 5.62 (s, 2H,
COCH2-). HRESIMS calcd for C13H10ClN6O4 and C13H9ClN6NaO4 m/z
[MþH]þ and [MþNa]þ 349.0447, 351.0422 and 371.0266, 373.0241
found 349.0448, 351.0422 and 371.0264, 373.0239.
4.2. Biological evaluation
4.2.1. In vitro screening
In vitro activity against T. cruzi, T. b. rhodesiense, L. donovani and
cytotoxicity assessment using L6 cells (rat skeletal myoblasts) was
determined using a 96-well plate format as previously described
[37]. Data were analyzed with the graphic program Softmax Pro
(Molecular Devices, Sunnyvale, CA, USA), which calculated IC50
values by linear regression from the sigmoidal dose inhibition
curves.
4.2.2. In vitro T. brucei antiproliferating assays and susceptibility
studies
The BSF of T. brucei parasites were seeded at 1  103 mL1 in
200 mL of growth medium containing different concentrations of
nitroheterocycle. Where appropriate, induction of the TbNTR was
carried out by adding tetracycline (1 mg/mL). After incubation for 3
days at 37 C, 20 mL of Alamar blue was added to each well and the
plates incubated for a further 16 h. The cell density of each culture
was determined as described before [20] and the IC50 established.
4.2.3. Enzymatic activity studies with type I TbNTR
Recombinant TbNTR was prepared and assayed as previously
described [38,39]. The speciﬁc activity of puriﬁed his-tagged TbNTR
was assessed spectrophotometrically at 340 nm using various
nitrotriazole substrates (100 mM) and NADH (100 mM) and
expressed as nmol NADH oxidized min1 mg1 of enzyme.
4.2.4. In vivo antichagasic activity assessment of selected
compounds
For in vivo studies, a Brazilian strain trypomastigotes from
transgenic T. cruzi parasites expressing ﬁreﬂy luciferase were used
as described before [15]. Brieﬂy, parasites (105 trypomastigotes)
were injected in 5 week-old Balb/c mice (Taconic) and three days
later mice were anesthesized by inhalation of isoﬂuorane, followed
by an injectionwith 150 mg/kg of D-luciferin potassium-salt in PBS.
Mice were imaged 5e10 min after injection of luciferin with an IVIS
100 (Xenogen, Alameda, CA) and the data acquisition and analysis
were performed with the software LivingImage (Xenogen) as
described before [40]. Treatment with test compounds started 4
days post infection at 13 or 15 mg/kg/day  10 days, given i.p. The
vehicle control was 2%methylcelluloseþ0.5% Tween 80 and groups
of 5mice/groupwere used. Micewere imaged after 5 and 10 days of
treatment. The ratio of parasite levels was calculated for each ani-
mal dividing the luciferase signal after treatment by the luciferase
signal on the ﬁrst imaging (before treatment). Mean values of all
animals in each group ± SD were used for plotting.
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